Researcher helps develop standards for safe use of histotripsy therapy

August 18, 2014

University of Cincinnati researchers are working with the U.S. Food and Drug Administration to develop a set of regulatory standards to ensure the safe and effective administration of histotripsy therapy used to treat patients with an enlarged prostate.

Histotripsy is a novel form of therapeutic ultrasound that can be applied transcutaneously (across the skin) to liquefy tissue. In addition to treating the prostate, it has applications for treatment of fetal ventricular defects, deep-vein thrombosis, and renal and liver cancer.

Kenneth Bader, PhD, postdoctoral fellow in the division of cardiovascular health and diseases at UC, says the gold standard for treating benign prostatic hyperplasia (BPH, an ) involves physicians using electrocautery or sharp dissection to remove tissue that is restricting urination in patients.

"Although the procedure is highly effective, there is also a significant rate of impotence in patients," says Bader. "Histotripsy is highly targeted and will give physicians a less invasive option."

"Instead of heating the tissue like in most forms of therapeutic ultrasound, histotripsy mechanically deforms it," says Bader. "So what happens is you have the small gas nuclei that are in your body and the ultrasound hits it and causes it to expand very rapidly and it collapses in a process termed cavitation. The mechanical action of that expansion and collapse of the cavitation is what liquefies the tissue to generate the therapy."

"It's like a scrubbing bubble, the same as a detergent breaking up dirt and grime, but in this case we are breaking up tissue," says Bader.

Currently, there are in which surgeons use a histotripsy device to emit ultrasound pulses from outside the patient's body into the prostate. These pulses form a bubble cloud within the prostate that mechanically breaks up the cellular structure of the soft tissue. The surgeon can direct the bubbled cloud to the intended treatment location.

UC researchers are not part of those clinical trials, but are working with the FDA to determine ways to regulate the output of these histotripsy devices as part of a $107,000 grant from the Focused Ultrasound Foundation.

Bader is the principal investigator and Christy Holland, PhD, professor in the division of cardiovascular health and diseases at UC and associate director of research for the UC Heart, Lung and Vascular Institute, along with Kevin Haworth, PhD, assistant professor in the division of cardiovascular health and disease at UC, are co-investigators.

"Will there be any collateral damage using histotripsy?" asks Bader. "Is there a good way to monitor the cavitation and monitor the histotripsy therapy? Part of what we are going to do is look at different settings on the histotripsy device. We are going to consider a range of ultrasound pulse durations. We are going to try to see where there is potential for collateral damage with the shortest and the longest pulse duration typically used on a histotripsy device.

"We look at not only how long is the pulse, but also how loud is the pulse," adds Bader. "We are looking at a soft tone versus a very loud tone. It's the range over which you can generate cavitation that depends on either how loud or how long the ultrasound pulse is."

"We will do numerical simulations to try and predict where the cavitation occurs and where the therapy occurs. These simulations will help with patient treatment planning," says Bader.

At some point what's helping to treat the prostate may help improve the of patients. Histotripsy has been used in animal models to try and break up tissues in the heart for the treatment of congenital heart diseases, and breaking up clots to treat deep-vein thrombosis.

"Right now it is just helping the FDA understand histotripsy for BPH, but that will open up a whole other flood gate of applications."

Explore further: New information on transcranial ultrasound therapy

Related Stories

New information on transcranial ultrasound therapy

August 4, 2014
A recent study completed at the University of Eastern Finland provides new information on the limitations and potential new directions for the future development of transcranial ultrasound therapy.

Study finds plasmin—delivered through a bubble—more effective than tPA in busting clots

May 15, 2013
A new study from the University of Cincinnati has found that, when delivered via ultrasound, the natural enzyme plasmin is more effective at dissolving stroke-causing clots than the standard of care, recombinant tissue plasminogen ...

FDA OKs implant for enlarged prostate symptoms

September 13, 2013
(AP)—Federal health regulators have approved the first permanent implant to treat men's urinary problems caused by an enlarged prostate.

Nonsurgical treatment for enlarged prostate on the horizon

June 23, 2014
You just cannot ignore your symptoms any longer. You find yourself getting up many times every night with the urgency to urinate. Saw palmetto, even high doses of the highest-quality type, didn't work.

New non-invasive technique controls size of molecules penetrating the blood-brain barrier

August 14, 2014
A new technique developed by Elisa Konofagou, associate professor of biomedical engineering and radiology at Columbia Engineering, has demonstrated for the first time that the size of molecules penetrating the blood-brain ...

Focal blood-brain-barrier disruption with high-frequency pulsed electric fields

August 12, 2014
A team of researchers from the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences have developed a new way of using electricity to open the blood-brain-barrier (BBB). The Vascular Enabled Integrated ...

Recommended for you

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.